METROPOLIS - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 3.0

📊 Analysis: Metropolis Healthcare is trading at ₹1,886, below DMA 50 (₹1,952) and DMA 200 (₹1,928), indicating short-term weakness. RSI at 31.1 suggests oversold conditions, but MACD negative (-18.3) confirms bearish momentum. Volume (38.9K) is slightly above 1-week average (35K), showing moderate intraday participation. Fundamentals are mixed — ROCE 13.4% and ROE 10.5% are modest, while P/E 73.2 vs industry 30.9 signals overvaluation. PAT improved sequentially (₹46.6 Cr. vs ₹35.6 Cr.), but overall valuation remains stretched. Intraday trades may be possible for speculative rebound near support.

💡 Optimal Buy Price: ₹1,875–₹1,890 (near support zone).

🎯 Profit-Taking Levels: ₹1,910 (first target), ₹1,940 (second target).

🛡️ Stop-Loss: ₹1,860 (below intraday support).

⏱️ If Already Holding: Exit near ₹1,910–₹1,940 if rebound occurs or RSI approaches 40+. Cut position below ₹1,860 with rising volume, as weakness may extend further.

Positive

• 📈 ROCE 13.4% and ROE 10.5% show moderate efficiency
• 💹 DII holding increased (+0.70%), showing domestic institutional support
• 📊 PAT improved sequentially from ₹35.6 Cr. to ₹46.6 Cr.
• 📉 Volume above average, supporting intraday participation

Limitation

• 📉 P/E 73.2 much higher than industry average (30.9)
• 📊 PEG ratio -5.24 indicates poor valuation relative to growth
• 📉 Price below DMA 50 & DMA 200, confirming bearish trend
• 📊 RSI oversold (31.1) signals weakness despite rebound potential

Company Negative News

• ⚠️ FII holding decreased (-0.31%), showing reduced foreign confidence
• ⚠️ High valuation compared to industry peers

Company Positive News

• ✅ DII holding increased (+0.70%), showing domestic support
• ✅ Sequential PAT improvement boosts sentiment

Industry

• 🏥 Industry PE at 30.9, Metropolis at 73.2 — highly overvalued
• 📊 Diagnostics sector remains defensive but faces valuation pressure

Conclusion

🔎 Metropolis Healthcare is a weak-to-moderate intraday candidate with bearish technicals and stretched valuations, though oversold RSI and sequential PAT improvement may trigger short-term rebound trades. Buy zone is ₹1,875–₹1,890 with targets at ₹1,910 and ₹1,940. Maintain strict stop-loss at ₹1,860. If already holding, exit near targets or cut losses below support with volume confirmation.

Would you like me to extend this into a peer benchmarking overlay with other diagnostic chains like Dr. Lal PathLabs and Thyrocare or a sector rotation basket scan to validate intraday opportunities?